by Chris Dokomajilar | Aug 14, 2023 | Analysis, Partnership Deals
Biopharma licensing activity in Q2 2023 was the lowest since 2019. Development and commercialization deals for the quarter came in at 110 deals for a total announced value of $28.2 billion with $1.2 billion in total upfront cash and equity. There were notable deals...
by Chris Dokomajilar | Aug 1, 2023 | Analysis, Funding, M&A, Partnership Deals
The biopharmaceutical industry outlook for the new quarter remains dynamic and promising, characterized by significant deals in the first half. Galderma’s private placement of $1 billion aims to strengthen its dermatology position and leverage its integrated...
by Chris Dokomajilar | Jun 15, 2023 | Analysis, Partnership Deals
So far, 2023 has witnessed a mixed landscape for R&D partnerships in the autoimmune sector. While there were notable activities and collaborations, there was a decline in the number of deals and the overall value compared to previous years. This suggests a...
by Chris Dokomajilar | Jun 8, 2023 | Analysis, Partnership Deals
Medtech R&D partnerships play a significant role in driving innovation and advancements in healthcare. Medtech’s various focus areas, such as medical devices, digital health solutions, and wearable technologies, saw active collaboration and investment, but...
